Orthofix Medical Inc
$ 9.23
-5.14%
11 Jun - close price
- Market Cap 373,092,000 USD
- Current Price $ 9.23
- High / Low $ 9.69 / 9.21
- Stock P/E N/A
- Book Value 10.78
- EPS -1.50
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.13 %
- 52 Week High 16.99
- 52 Week Low 9.13
About
Orthofix Medical Inc. is a medical device and biological products company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. The company is headquartered in Lewisville, Texas.
Analyst Target Price
$15.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.11 | 0.2378 | -0.57 | 0.13 | -0.03 | 0.0154 | 0.07 | 0.05 | 0.11 | 0.03 | 0.07 | 0.02 |
| Estimated EPS | -0.29 | -0.22 | -0.41 | 0.04 | -0.27 | -0.05 | -0.15 | -0.19 | -0.33 | -0.08 | -0.21 | -0.47 |
| Surprise | 0.18 | 0.4578 | -0.16 | 0.09 | 0.24 | 0.0654 | 0.22 | 0.24 | 0.44 | 0.11 | 0.28 | 0.49 |
| Surprise Percentage | 62.069% | 208.0909% | -39.0244% | 225% | 88.8889% | 130.8% | 146.6667% | 126.3158% | 133.3333% | 137.5% | 133.3333% | 104.2553% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OFIX
2026-06-11 10:39:42
Orthofix Medical Inc. announced that its shareholders approved an amendment to its Second Amended and Restated Stock Purchase Plan, adding 1,250,000 common shares for issuance. This amendment was one of several items approved at the 2026 Annual Meeting of Shareholders, where a quorum was present, and director nominees received substantial support. The changes aim to further align employee and shareholder interests without altering other plan terms.
2026-06-03 19:10:44
This article provides an analysis of Orthofix Medical Inc. (OFIX) stock, including its current price, fundamental financials, and corporate actions. It details the company's segments in orthopedic and spine solutions and offers a guide on how to buy OFIX stock through the Gotrade app. The piece also addresses frequently asked questions regarding minimum investment, dividends, and market hours.
2026-06-02 16:10:03
Faruqi & Faruqi, LLP is investigating potential claims against Orthofix Medical Inc. (NASDAQ: OFIX) and encourages investors who suffered losses exceeding $75,000 to contact them. The investigation follows a federal securities class action filed against the company concerning allegedly false and misleading statements about its management team, which led to a significant stock price drop. Investors have until October 21, 2024, to seek the role of lead plaintiff.
2026-05-30 04:09:16
Faruqi & Faruqi, LLP is investigating potential claims against Orthofix Medical Inc. (NASDAQ: OFIX) on behalf of investors who suffered losses exceeding $75,000 between October 11, 2022, and September 12, 2023. The investigation follows a significant drop in Orthofix's stock price after the company announced the termination of its CEO, CFO, and Chief Legal Officer for violating code of conduct requirements. Investors are reminded of the October 21, 2024 deadline to seek the role of lead plaintiff in the federal securities class action.
2026-05-30 02:09:16
Juniper Investment Company, a 10% owner of Orthofix Medical Inc. (NASDAQ:OFIX), sold 242,000 shares of common stock for approximately $2.59 million on May 22, 2026. This transaction occurred as OFIX stock trades near its 52-week low. The sale follows Orthofix Medical's first-quarter 2026 earnings beat but an updated financial outlook for 2026 due to anticipated Medicare reimbursement declines for bone growth stimulators.
2026-05-30 02:09:16
Orthofix Medical (OFIX) is facing renewed activist investor pressure, reminiscent of a 2009 campaign, due to its declining stock performance, strategic shifts like discontinuing M6 product lines, and insider selling. Despite a "Hold" consensus from analysts and a potential 44% upside to the average price target of $20.00, the company grapples with merger integration challenges, unprofitability, and legal issues. The article suggests a "Hold" rating for existing shareholders, advising new investors to await clearer signs of operational improvement and stability.
